Anti-VEGF thwarts retinal nonperfusion progression in eyes with BRVO, CRVO

Ranibizumab reduced retinal nonperfusion in eyes with macular edema stemming from retinal vein occlusion, according to a study.Data were culled from the BRAVO and CRUISE studies, which evaluated the safety and efficacy of Lucentis (ranibizumab, Genentech) intraocular injections in patients with macular edema following retinal vein occlusion.

Full Story →